Precision Medicine Group Appoints John Hubbard, PhD, as Board of Directors Chair
Retrieved on:
Monday, March 13, 2023
PMG, Strategic planning, Science 37, Toxicology and Applied Pharmacology, Doctor of Philosophy, Senior, Translation, Pharmacology, American College of Clinical Pharmacology, Science, Diplomate of National Board, Enterprise, American College, Personalized medicine, Development, Drug development, ChromeOS, ICON, DevOps, ICON PLC, Pfizer, Management, Nursing
BETHESDA, Md., March 13, 2023 /PRNewswire/ -- Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointment of John Hubbard, PhD, as Chairman of its Board of Directors.
Key Points:
- BETHESDA, Md., March 13, 2023 /PRNewswire/ -- Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointment of John Hubbard, PhD, as Chairman of its Board of Directors.
- "We are thrilled to welcome John to our Board.
- He is a highly regarded leader in the pharmaceutical industry with extensive experience in clinical development and operations, strategic planning and business development," said Mark Clein, Chief Executive Officer of Precision Medicine Group.
- Earlier, he was Group President of ICON plc's Global Clinical Research Services Division, one of the top five global CROs.